Aqua Lung Welcomes World-Renowned Wildlife Photographer and Conservationist Paul Nicklen as a Global Ocean Ambassador
26.1.2021 14:00:00 EET | Business Wire | Press release
Aqua Lung, the celebrated pioneer, designer, manufacturer and distributor of dive and watersports equipment for 75 years, today announced world-renowned wildlife photographer and conservationist Paul Nicklen is joining the brand as a global ocean ambassador. As part of the partnership, Nicklen will exclusively use Aqua Lung, Apeks, and O.ME.R. products during all dive expeditions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210126005122/en/
Aqua Lung global ocean ambassador and SeaLegacy co-founder, Paul Nicklen with co-founder and President of SeaLegacy, Cristina Mittermeier. Photo credit: Joe Leahy
Nicklen, best-known for his incomparable underwater photography and ocean conservation efforts, will utilize the full range of industry-leading Aqua Lung, Apeks and O.ME.R. products from wetsuits, masks and fins to technical gear and regulators. Helping to grow the brand globally, Nicklen joins an elite roster of ambassadors at Aqua Lung including, Philippe Cousteau Jr., Ashlan Gorse Cousteau, and Greg Lecoeur.
“From day one, the Aqua Lung family has been kind and unwavering in their support of our mission to build community and restore the health and abundance of our oceans,” said Nicklen. “Personally, I love the simplicity and quality of the Aqua Lung products and I’m grateful the entire SeaLegacy team gets to use them. Most importantly, the products are reliable and give me the ability to focus on filming and being a photographer and conservationist.”
Paul Nicklen is a Canadian photographer and marine biologist specializing in the polar regions and their wildlife. Nicklen has completed more than 20 assignments for National Geographic and in 2014, co-founded SeaLegacy, a non-profit organization that propelled ocean conservation onto the world stage through the power of visual storytelling, impact campaigns and the funding of sustainability projects. In 2019, Nicklen was inducted into the International Photography Hall of and in that same year, was appointed to the Order of Canada.
“We are thrilled to welcome Paul Nicklen to the Aqua Lung family,” said Laurent Boury, Senior Vice President of Brands for the Aqua Lung Group. “Paul is an incredibly talented photographer and an important voice in ocean conservation, and we are honored that he chooses to use Aqua Lung, Apeks, and O.ME.R. products to further his work.”
Nicklen and the crew from SeaLegacy are slated to spend the next six months in the Bahamas, focusing on the development of an immersive content series to inspire and galvanize a global audience, shedding light on critical threats, tipping points, and scalable solutions unique to the region. Against the backdrop of Hurricane Dorian’s still ongoing recovery efforts and the ongoing Covid-19 pandemic, Nicklen and his team are documenting one of the most complex, yet promising, conservation stories as it unfolds. Using SeaLegacy’s storytelling expertise and Only One’s data-driven content delivery formula, this expedition will build a robust library of assets and supporting content that can be organized into actionable narratives and educational curriculum.
To learn more or to see Nicklen’s work, go to paulnicklen.com or follow him on Instagram. For more information about Aqua Lung products, visit AquaLung.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210126005122/en/
Contact information
Lauren Schuil
lschuil@aqualung.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 13:00:00 EET | Press release
Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022786567/en/ David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck "For people living with TGCT, the impact of the disease is often felt through persis
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release
WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release
Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom